AZ-WL-GORE-&-ASSOCIATES
W. L. Gore & Associates, Inc. (Gore) today announced that the GORE® VIABAHN® Endoprosthesis has received CE Mark approval to improve blood flow in symptomatic obstruction of peripheral veins, excluding the venae cavae and pulmonary veins.
“The GORE VIABAHN Endoprosthesis is a welcome addition to options available for treating stenosis in the dialysis access circuit,” said Peter Riley, MD, Consultant Interventional Radiologist at the Queen Elizabeth Hospital Birmingham, United Kingdom. “It has a proven track record in maintaining patency in central chest vein stenosis as confirmed by our recently published single-center study. It is extremely flexible, allowing deployment across anatomical sites of movement and flexion. The Gore REVISE Clinical Study indicates improved patency compared to PTA in the graft to vein anastamosis and has demonstrated similar outcomes to draining veins, particularly at the cephalic arch, in my practice.”
In the Gore REVISE Clinical Study (AVR 06-01), the GORE VIABAHN Device group demonstrated statistical superiority of target lesion primary patency as compared to PTA (p = 0.008).
With a long history of iliac and superficial femoral artery use, the GORE VIABAHN Device is the lowest profile, most flexible, self-expanding, small-diameter, endoprosthesis available. It is constructed with a durable, reinforced, biocompatible, expanded polytetrafluoroethylene (ePTFE) liner and attached to an external nitinol stent structure. The ePTFE luminal surface of the GORE VIABAHN Endoprosthesis incorporates the CBAS® Heparin Surface. This heparin technology consists of a proprietary, covalent end-point attachment to the graft surface that is intended to provide sustained thromboresistance.
“We are pleased to expand the GORE VIABAHN Endoprosthesis to hemodialysis access in Europe,” said Ray Swinney, Business Unit Leader for the Gore Peripheral Interventional Business Unit. “We are committed to exceeding the expectations of vascular surgeons, interventional radiologists, and interventional nephrologists who have been seeking a better solution for their dialysis access patients.”
ABOUT W. L. GORE & ASSOCIATES
The Gore Medical Products Division has provided creative therapeutic solutions to complex medical problems for more than 35 years. During that time, more than 35 million innovative Gore Medical Devices have been implanted, saving and improving the quality of lives worldwide. The extensive Gore Medical family of products includes vascular grafts, endovascular and interventional devices, surgical meshes for hernia repair, soft tissue reconstruction, staple line reinforcement and sutures for use in vascular, cardiac, and general surgery. Gore is one of a select few companies to appear on all of the U.S. “100 Best Companies to Work For” lists since the rankings debuted in 1984. For more information, visit www.goremedical.com .
GORE® , VIABAHN® , and designs are trademarks of W. L. Gore & Associates. CBAS® is a trademark of Carmeda AB, a wholly owned subsidiary of W. L. Gore & Associates.
Contact:
Chempetitive Group for W. L. Gore & Associates
Kena Hudson or
Jordona Jackson Smith, 510-908-0966
GoreMedical@Chempetitive.com
Link:
Information om Business Wire
Følg pressemeddelelser fra Business Wire
Skriv dig op her, og modtag pressemeddelelser på e-mail. Indtast din e-mail, klik på abonner, og følg instruktionerne i den udsendte e-mail.
Flere pressemeddelelser fra Business Wire
Incyte To Present Initial Data for its TGFβR2×PD-1-directed Bispecific Antibody (INCA33890) and its Selective Inhibitor of G12D-mutated KRAS (INCB161734) at the European Society of Medical Oncology (ESMO) Congress 202524.7.2025 23:02:00 CEST | Press release
- Mini oral presentation to highlight initial Phase 1 data of INCA33890, a promising TGFβR2×PD-1-directed bispecific antibody, in patients with advanced or metastatic solid tumors - Oral presentation to feature initial data of INCB161734, a novel, selective and orally bioavailable inhibitor of G12D-mutated KRAS, in patients with advanced or metastatic solid tumors with KRASG12D mutations Incyte (Nasdaq:INCY) today announced that the Company will present key data from its oncology portfolio at the upcoming European Society of Medical Oncology (ESMO) Congress 2025, to be held October 17-21 in Berlin. “We're looking forward to presenting the latest findings across our oncology portfolio at this year’s congress, including initial data for our TGFβR2×PD-1-directed bispecific antibody, INCA33890, and our novel, selective and orally bioavailable inhibitor of G12D-mutated KRAS, INCB161734,” said Pablo J. Cagnoni, M.D., President and Head of Research and Development, Incyte. “These data undersc
DNIB.com Reports Internet Has 371.7 Million Domain Name Registrations at the End of the Second Quarter of 202524.7.2025 23:01:00 CEST | Press release
VeriSign, Inc. (NASDAQ: VRSN), a global provider of critical internet infrastructure and domain name registry services, today announced that, according to the latest Domain Name Industry Brief Quarterly Report from DNIB.com, the second quarter of 2025 closed with 371.7 million domain name registrations across all top-level domains (TLDs), an increase of 3.3 million domain name registrations, or 0.9% compared to the first quarter of 2025. Domain name registrations also increased by 9.3 million, or 2.6%, year over year. The .com and .net TLDs had a combined total of 170.5 million domain name registrations in the domain name base at the end of the second quarter of 2025, an increase of 0.7 million domain name registrations, or 0.4% compared to the first quarter of 2025. The .com and .net TLDs had a combined decrease of 0.1 million domain name registrations, or 0.1%, year over year. As of June 30, 2025, the .com domain name base totaled 157.9 million domain name registrations and the .net
SES and the Luxembourg Government to Develop and Launch New Defence Satellite for GovSat24.7.2025 18:55:00 CEST | Press release
GovSat-2 is aimed at meeting growing demand for highly secure, flexible MILSATCOM services SES and the Luxembourg Government today announced their plan for development of a second satellite for GovSat (LuxGovSat S.A.), the public-private partnership and 50/50 joint venture between SES and the Luxembourg Government that provides secure, reliable and accessible satellite communication services for governments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250724379713/en/ GovSat-2. Copyright: Thales Alenia Space GovSat-2 will be positioned over the European satellite arc. It will join GovSat-1 in augmenting reliable connectivity services for government customers over the region. The satellite will be built by Thales Alenia Space on its Spacebus 4000B2 platform. Since launching in 2018, the joint venture’s first defence satellite, GovSat-1, operated by GovSat from a secure missions operations centre in Luxembourg, has supporte
Infobip Named a Leader in 2025 Gartner® Magic Quadrant™ for Communications Platform-as-a-Service for the Third Consecutive Year24.7.2025 18:21:00 CEST | Press release
Infobip positioned furthest in Completeness of Vision Global communications platformInfobiphas once again been named a Leader in the 2025 Gartner Magic Quadrant for Communications Platform-as-a-Service (CPaaS)1. This year the company is placed furthest in Completeness of Vision. Infobip views this third consecutive recognition as acknowledging its status as a global CPaaS powerhouse. Magic Quadrant2 reports are a culmination of rigorous, fact-based research in specific markets, providing a wide-angle view of the relative positions of the providers in markets where growth is high and provider differentiation is distinct. Providers are positioned into four quadrants: Leaders, Challengers, Visionaries and Niche Players. The research enables customers to get the most from market analysis in alignment with their unique business and technology needs. As a Leader, Infobip is recognized for both its Ability to Execute and its Completeness of Vision. Infobip powers conversations for some of the
Andersen Consulting fremmer digitale transformationsmuligheder med eksponentielle digitale løsninger24.7.2025 17:43:00 CEST | Pressemeddelelse
Andersen Consulting fortsætter med at opbygge sin digitale konsulentplatform gennem et samarbejde med Exponential Digital Solutions (10xDS), et firma der specialiserer sig i AI-drevet transformation og nye teknologier. 10xDS blev stiftet i 2016 af adminstrerende direktør Binu Koshy og leverer next generation-løsninger inden for automatisering, analyse, kunstig intelligens, cybersikkerhed og udvikling af digitale produkter. Virksomhedens tværfaglige tilgang kombinerer teknisk ekspertise med strategisk indsigt og støtter kunderne i deres implementering og skalering af next generation-løsninger. Med international erfaring inden for forskellige brancher arbejder 10xDS på at løse operationelle ineffektiviteter og skabe ny værdi gennem digital innovation. "Hos 10xDS har vi opbygget en organisation, der er baseret på innovation og troen på, at AI og nye teknologier kan føre til betydeligt bedre forretningsresultater," siger Binu. "Dette samarbejde understøtter vores mission om at skalere tran
I vores nyhedsrum kan du læse alle vores pressemeddelelser, tilgå materiale i form af billeder og dokumenter samt finde vores kontaktoplysninger.
Besøg vores nyhedsrum